Active SIRT7, human recombinant protein
NAD-dependent deacetylase 7; SIR2-like protein 7; Sirtuin 7; SIR2L7; Silent Information Regulator 7
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9NRC8 |
---|---|
Concentration | 2 |
Calculated MW | 50.1 kDa (2-400 aa + N-terminal polyhistidine tag). |
Gene ID | 51547 |
---|---|
Gene Symbol | SIRT7 |
Other Names | NAD-dependent deacetylase 7; SIR2-like protein 7; Sirtuin 7; SIR2L7; Silent Information Regulator 7 |
Gene Source | Human |
Source | E. coli |
Assay&Purity | SDS-PAGE; ≥85% |
Assay2&Purity2 | HPLC; |
Recombinant | Yes |
Results | >1 µU/mg |
Sequence | 2-400 aa |
Target/Specificity | SIRT7 |
Format | Liquid |
Storage | -80°C; 2 mg/ml in 50 mM Tris, pH 8.0, 100 mM NaCl, containing 5 mM DTT and 20% glycerol. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The sirtuins represent a distinct class of trichostatin A-insensitive lysyl-deacetylases (class III HDACs) and have been shown to catalyze a reaction that couples lysine deacetylation to the formation of nicotinamide and O-acetyl-ADP-ribose from NAD+ and the abstracted acetyl group. There are seven human sirtuins, which have been designated SIRT1-SIRT7. Recently, SIRT7 has been shown to activate transcription by RNA polymerase I and deacetylate p53. SIRT7 prevents progressive functional deterioration of the heart, and is suggested to play an important role in regulation of stress responses and cell death in the heart.
References
Frye R.A.,et al.Biochem. Biophys. Res. Commun. 273:793-798(2000).
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Zody M.C.,et al.Nature 440:1045-1049(2006).
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
de Nigris F.,et al.Br. J. Cancer 86:917-923(2002).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.